HHS buying $290M worth of Amgen drug Nplate for radiation sickness in nuclear emergency

Oct. 04, 2022 6:24 PM ETAmgen Inc. (AMGN)By: Jonathan Block, SA News Editor15 Comments

Sign of radioactive danger depicted on a concrete wall

Nikolay Chekalin

  • HHS is purchasing $290M worth of Amgen's (NASDAQ:AMGN) Nplate (romiplostim) for acute radiation sickness due to a radiological or nuclear emergency.
  • The treatment was developed by the company with assistance from the Biomedical Advanced Research and Development Authority and National Institute of Allergy and Infectious Diseases.
  • Nplate is approved for immune thromocytopenia, a blood disorder characterized by low platelet counts.

Recommended For You

Comments (15)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.